The abrdn Global Infrastructure Income Fund (ASGI) recently completed a rights offering that diluted its net asset value and pressured its share price, resulting in the fund trading at a discount. Despite this, the fund now offers a 13.62% yield and provides exposure to global and private infrastructure assets, making it an attractive entry point for investors. The fund's diversification and positive long-term outlook on infrastructure support its inclusion in portfolios, alongside other top infrastructure picks like DPG. This opportunity was highlighted by Nick Ackerman, an experienced investor and contributor to the CEF/ETF Income Laboratory community.
Regarding the abrdn Global Infrastructure Income Fund (ASGI), here is Pluang's market snapshot as of Oct 21, 2026 00:31 WIB: Out of 150 priced US stocks tradable on Pluang, 112 rose and 38 fell today. Notable movers include General Motors Company (GM) at USD 75.44 with a 1-day change of -8.83%, Sea Limited (SE) at USD 81.19 down 8.23%, and BlackBerry Limited (BB) at USD 8.77 up 7.48%. The most notable figure is the 100% buy order activity for GM on Pluang.
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...
Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...
